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Background: The prevalence of fibromyalgia increases worldwide and is characterized by widespread and chronic
pain. Treatment is difficult and includes both drug and non-drug approaches. Milnacipran, an antidepressant, is used
for fibromyalgia, with a possible beneficial effect on central pain modulation. Our hypothesis is that the efficacy of
milnacipran in fibromyalgia depends on the performance of pain inhibitory controls.
Methods/design: A randomized, double blind, clinical trial (NCT01747044) with two parallel groups, in 48 women
with fibromyalgia, is planned in the Clinical Pharmacology Center, University Hospital, Clermont-Ferrand, France.
Conditioned pain modulation (estimated with thermal stimuli using a numeric pain rating scale), the primary
endpoint measure, is evaluated before and one month after treatment with milnacipran or placebo. Secondary
outcome measures include the predictability of pain descending pathways performance for milnacipran efficacy,
tolerance and cognitive function. Data analysis is performed using mixed models; the tests are two-sided, with
a type I error set at alpha = 0.05. Not only will this trial allow estimation of the beneficial effect of milnacipran
on pain and on descending pain pathways but it will also evaluate whether the performance of this modulatory
system could be predictive of its efficacy in alleviating pain.
Discussion: This method would allow clinicians to take a pro-active attitude by performing a rapid psychophysical
test before starting milnacipran treatment and would avoid unnecessary prescription while preventing therapeutic
failure in patients who often face this recurrent problem.
Trial registration: ClinicalTrials.gov NCT01747044.
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Fibromyalgia has a prevalence estimated at 2 to 5% of
the general population in Europe [1] and in the United
States of America [2] and is approximately seven times
more common in women than in men [3]. Diagnostic
criteria have been validated since 1990 by the American
College of Rheumatology and have been enlarged in the
2010 revision to consider not only tender points but also* Correspondence: gisele.pickering@udamail.fr
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[4]. The pathophysiology of fibromyalgia is uncertain but
a dysfunction of descending pain inhibitory pathways
[5-7] has been described as a cause or a consequence of
the pathology [8]. These pathways originate in the brain-
stem and are involved in diffuse noxious inhibitory con-
trols (DNICs) that are part of a central pain modulatory
system relying on spinal and supraspinal mechanisms
[9]. This pain modulatory system can be easily triggered
and studied in experimental settings [10,11] using the
conditioned pain modulation test, where the admi-
nistration of two simultaneous painful stimuli typically
results in pain inhibition [12,13]. Stimulation of DNICs. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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descending pain modulation.
Antidepressants have a mechanism of action that
involves a number of neuromediators (serotonin, nor-
adrenaline) within the brain-brainstem-spinal-cord axis
and affects pain descending pathways [14]. Duloxetine
and milnacipran are serotonin and norepinephrine re-
uptake inhibitors and have been approved for treatment
of fibromyalgia by the Food and Drug Administration
[15-17] for their analgesic properties [14]. Experiments
on the safety, tolerability, and clinical benefits of long-
term milnacipran use in patients with fibromyalgia have
shown good results [18]. A review of four double blind
studies focused on the efficacy of milnacipran in fibro-
myalgia [18]: a substantial improvement on global status
was observed and more than 30% pain relief was
obtained but only in 40% patients.
Considering this large variability in response to milna-
cipran, it is expected that a number of patients will have
no alleviation of pain: it would be beneficial for the pa-
tient to be able to predict the efficacy of milnacipran in
pain associated with fibromyalgia before the prescription
of the drug. It would also be important to evaluate cog-
nitive function, which is frequently impaired in chronic
pain [19]. This information would enable prescription of
the drug to be avoided if no efficacy is expected, and
would avoid therapeutic failure in patients who often
stop their treatment because of lack of efficacy. Such a
predictive approach has been performed with duloxetine
in another pathology, painful diabetic neuropathy [13],
where the authors have shown that pain alleviation
may be predicted from pre-treatment conditioned pain
modulation. Such an approach is quite interesting in
the context of milnacipran as DNICs are involved in
the mechanism of action of both drugs [12,17]. In this
trial, we set the mechanistic hypothesis that (1) milna-
cipran restores the function of descending inhibitory
pathways and concomitantly decreases the pain expe-
rience in fibromyalgia patients, and (2) this efficacy
could be predicted from the performance, before treat-
ment, of pain descending pathways when activated by
conditioned pain modulation.
Methods/design
This study is a prospective, randomized, controlled,
double blind clinical trial of two parallel groups, milnaci-
pran versus placebo, in 48 fibromyalgia patients. It is
carried out in the Pain Clinic and Clinical Pharmacology
Center, University Hospital, Clermont-Ferrand, France.
The research ethics committee (Comité de Protection
des Personnes Sud-Est 6) gave its approval on October,
18, 2012 (institutional review board number 00008526/
AU987), and the Agence Nationale de Sécurité du
Médicament et des Produits de Santé on September, 25,2012, and this trial is registered in ClinicalTrials.gov
(trial number NCT01747044).
Patients come twice to the Pain Clinic and Clinical
Pharmacology Center, for inclusion and randomization
and 1 month later for reassessment.
Eligibility criteria are verified with a complete clinical
exam, matching the American College of Rheumatol-
ogy’s definition of fibromyalgia. Patients meeting the
inclusion criteria sign a consent form after receiving oral
and written information about the study. At baseline,
pain is assessed by a numeric pain rating scale and
patients undergo psychophysical and cognitive ability
tests. Patients are then randomly assigned to milnaci-
pran (n = 24) or placebo (n = 24) for one month’s treat-
ment, with the following titration: 50 mg on the first
three days, 75 mg from day 4 to day 6 and 100 mg from
day 7 to 1 month. Evaluations and tests are then
repeated 1 month later at visit 2. To maintain good
compliance and to verify adverse events, patients are
telephoned once a week by a clinical research assistant
until visit 2.
Objectives
The primary objective of this trial is to assess whether
milnacipran has an influence on DNIC status, by meas-
uring if there is a difference between the results of the
conditioned pain modulation test in milnacipran and
placebo groups.
The secondary objectives are to assess:
 Whether the DNIC status could be predictive of
milnacipran efficacy in fibromyalgia,
 The evolution of pain threshold with milnacipran,
 The impact of milnacipran on cognitive parameters;
comprehension tests, executive function, memory,
attention and decision making,
 Tolerance towards milnacipran.
Participants and setting
Inclusion criteria
Patients are eligible for this study if they are over
18 years old with a confirmed diagnosis of fibromyalgia,
are able to understand and willing to follow the study
protocol and have given informed consent.
Exclusion criteria
Patients will not be accepted if there is contra-indication
of milnacipran treatment, if they have hypertension or
heart disease, known renal impairment, a medical or
surgical history incompatible with the study, or a psychi-
atric disorder, or if they have shown signs of suicidal
behavior or significant suicidal ideas. This study also
excludes patients with diabetes, patients with acute and
chronic intoxication with alcohol, hypnotics, analgesics,
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cing hyponatremia, patients taking non-steroidal anti-
inflammatory drugs, oral anticoagulants, aspirin or other
drugs that are likely to induce bleeding, and patients
taking drugs with serotonin and noradrenaline reuptake
inhibition, digitalis, cytochrome P450 1A2 inhibitors, or
5-hydroxytryptamine serotonin receptor agonist. Women
of childbearing age not using an effective contraceptive
will be excluded, as will pregnant or breastfeeding
women, patients taking part in another interventional
trial or patients unable to understand the patient infor-
mation and the informed consent form.
Eligibility and randomization
Patients are recruited during their admission to the
Pain Clinic and Clinical Pharmacology Center. Before
enrolment, informed consent is obtained from each
patient in the presence of the investigator. Randomization
will be conducted to balance group sizes according to
a computer-generated allocation sequence by blocks
with Stata software by a statistician independent of the
protocol [20]. The randomization sequence is gener-
ated using random blocks and the size of the blocks is
unknown, to avoid guessing during the trial. Subjects
are then randomized to milnacipran or placebo groups.
Double blinding will be fully respected with the pa-
tients and the members of staff. A research nurse who
is only involved in drug allocation will be in charge of
drug administration. Treatments are prepared in the
Central Pharmacy of the University Hospital with
double blinding according to Good PharmaceuticalTable 1 Summary of evaluation for a patient




Inclusion and exclusion criteria ×
Clinical examination: diagnosis of fibromyalgia ×
Measures
Numeric pain rating scale ×
Assessment of pain threshold to a thermal stimulus ×
Test-stimulus intensity ‘pain 60/stimulus’ ×
Conditioned pain modulation test ×
Cantab® tests ×
Treatment
Randomization: delivery of therapeutic units ×
Reporting of adverse events and concomitant treatments ×
Treatment compliance
Reporting of adverse events and concomitant treatments ×
Return of therapeutic unitsPractice. The milnacipran and placebo will be adminis-
tered in the form of white capsules that look alike.
Definition of outcome measures
Primary outcome measure
The primary outcome measure is the change of condi-
tioned pain modulation effect induced by milnacipran
compared with placebo.
Secondary outcome measures
Secondary outcome measures are the assessment of the
evolution of pain threshold, DNIC status, milnacipran
efficacy and tolerance, and cognitive status.
The summary of the different evaluations and tests is
reported in Table 1.
Conditioned pain modulation
Conditioned pain modulation is evaluated before treat-
ment randomization (visit 1, CPMv1) and after 1 month
treatment (visit 3, CPMv3). The milnacipran and placebo
differences (CPMv3 −CPMv1) are then compared. With
pain intensity rated by the patient on a numeric scale
from 0 (no pain) to 100 (worst pain possible), the condi-
tioned pain modulation is obtained with the following
experiment. An Advanced Thermal Stimulator thermode
(Medoc Ltd, Ramat Yishai, Israel) is applied to the volar
side of the patient’s dominant forearm. The Medoc
PATHWAY system delivers stimulation at the predeter-
mined pain threshold for 10 seconds and the patient
rates her pain using the numeric scale. Then the Medoc
PATHWAY system delivers a stimulus at the samePhone call Visit 2
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pain using the numerical scale. After the end of these
two stimuli (15 minutes), the patient puts the non-
dominant hand into a water bath at 46.5°C for 60 sec-
onds. After having dried her hand, the patient has a
similar sequence of stimuli for 10 and 30 seconds with
pain evaluation using the numeric pain rating scale. The
aim of this test is to trigger the stimulation of pain
descending pathways. If these pathways are functional,
the second series of stimuli will be less painful than the
first one because of the inhibitory effect on pain stimuli.
It is the reverse if these pathways are not functional, as
described in a number of chronic pain situations in-
cluding fibromyalgia [11,21]. The amplitude of the
conditioned pain modulation is given by the difference
between the pain scores on the numeric pain rating
scale before and after the immersion of the non-
dominant hand.
Assessment of pain thresholds with a thermal stimulus
The Advanced Thermal Stimulator thermode (30 ×
30 mm) connected to the Medoc PATHWAY system is
applied to the volar side of the patient’s dominant fore-
arm. From the baseline value of 32°C, the Medoc PATH-
WAY system delivers an adjustable temperature peak (in
cold and heat, depending on a regular increase of 1°C
increments) and is controlled by rapid feedback. This
device is used to evaluate the pain threshold to heat and
cold by calculating the mean of three measures. This
technique was recently used successfully in neurophysi-
ology studies in human beings [11] and showed similar
results to those obtained with a laser [22].
Test-stimulus intensity ‘pain 60/stimulus’
The Advanced Thermal Stimulator thermode is applied
to the volar side of the patient’s dominant forearm. From
the baseline value of 32°C, the PATHWAY system
delivers a series of peaks starting at 1°C above the pain
threshold. Then the temperature increases by 1°C until
the patient rates the pain intensity as equivalent to 6/10
on the numeric pain rating scale.
Cognitive tests
The Cambridge Neuropsychological Test Automated
Battery (Cantab®, Cambridge, UK) [19] is a battery of
22 neuropsychological tests, administered to subjects
using a touch screen computer and a press-pad. The
tests selected are: Motor Screening Test, Stockings of
Cambridge, Reaction Time, Cambridge Gambling Task,
and Graded Naming Test.
Data handling and record keeping
All original records, such as consent forms and case
report forms, will be archived at the trial site for 15 years.The database file will be anonymized and will also be
maintained for 15 years.Sample size calculation
According to our previous work and a study of the
literature [13], we calculate that a sample size of n = 24
patients per randomized group would provide 90% stat-
istical power of detecting an absolute difference of 15
points in the primary outcome, that is, the conditioned
pain modulation difference between milnacipran and
placebo (with a standard deviation of conditioned pain
modulation variation equal to 16 points), at a two-sided
alpha level of 0.05. A total of 48 patients will be
included.Statistical analysis
Statistical analysis will be conducted on an intention-to-
treat principle using Stata software, version 13 (Stata-
Corp, College Station, TX, USA). A two-sided P value of
less than 0.05 will be considered to indicate statistical
significance. Baseline characteristics will be presented
for each randomized group as the mean ± standard devi-
ation or the median (interquartile range) according to
statistical distribution for continuous data, and as the
number of patients and associated percentages for cat-
egorical parameters. Comparisons between independent
groups will be analyzed using the Chi squared or Fisher’s
exact test for categorical variables, and by Student’s
t-test or the Mann–Whitney test for quantitative
parameters (notably primary outcome, temporal sum-
mation, test-stimulus intensity ‘pain 60/stimulus’, pain
rating on the numeric pain rating scale, cognitive pa-
rameters, with normality verified by the Shapiro-Wilk
test and homoscedasticity by the Fisher-Snedecor test.
As suggested by Vickers and Altman [23], the primary
analysis will be completed by an analysis of covariance
considering conditioned pain modulation at 1 month
as a dependent variable, and group and baseline value
of conditioned pain modulation as independent param-
eters. Finally, to study whether the DNICs (assessed
using the conditioned pain modulation test) in patients
with fibromyalgia would be predictive of milnacipran
efficacy, multivariate models such as regression ana-
lysis (milnacipran efficacy evaluated by conditioned
pain modulation difference taken as a dependant variable
[13]) will be performed considering the randomization
group and the baseline values of conditioned pain modu-
lation and pain as covariables. Secondarily, a sensitivity
analysis concerning missing data will be considered to
study their nature (not missing at randomization, missing
at randomization and so on) and to propose the most
appropriate imputation approach.
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Evaluation of predictive factors of pain development and
pain alleviation is very important for treatment opti-
mization [24]. Pain alleviation in fibromyalgia is very
difficult, as the response to analgesics is very variable.
Milnacipran is particularly recommended for the man-
agement of fibromyalgia [16] but only 40% of patients
are relieved (30% less pain) [18]. Adding to this high
variability in the response to milnacipran, discontinu-
ation of treatment is also due to adverse events in 25%
of patients compared with 12% in those receiving
placebo [25]. Considering that many patients have no
improvement of pain symptoms, it is therefore import-
ant to explore the status of the pain modulatory system
and evaluate whether DNICs could be a predictive factor
of the efficacy of milnacipran in patients with fibromyal-
gia. The comparison of the performance of descending
inhibitory pathways when triggered by a painful stimu-
lus before and after treatment gives information on
the amplitude of pain modulation and control. It may
help to predict non-responders, as shown for duloxe-
tine [13], and identify the risk of developing chronic
post-operative pain [26]. This study aims first to evalu-
ate the state of functioning of the DNICs in patients
with fibromyalgia and then to estimate if it might be a
predictive factor of pain alleviation. If such an impact
is demonstrated, clinicians could perform a simple psy-
chophysical test to test the DNIC performance before
prescribing milnacipran. Considering the tight links
between chronic pain and cognitive impairment [19],
the study will also assess the impact of milnacipran on
several cognition domains. This approach could help
to optimize treatment, would avoid useless prescrip-
tion, prevent unnecessary adverse events, and, more
generally, would prevent recurrent therapeutic failure
in non-responder patients.
Trial status
Recruitment started in April 2013. At the time of
writing, 26 patients had been recruited.
Abbreviations
CPMv1: conditioned pain modulation test, visit 1; CPMv3: conditioned pain
modulation test, visit 3; DNIC: diffuse noxious inhibitory control.
Competing interests
The authors declare that there are no financial or non-financial competing
interests, neither within the conception nor within the conduction of the
trial.
Authors’ contributions
GP is the overall study principal investigator; she participated in the
conception and study design and contributed to the writing of the study
protocol and the drafting and editing of this manuscript. NM, CS, CD, and
BP all participated in the study design. BP, NM, and CD contributed to
the writing of the study protocol. BP carried out all statistical calculations
and wrote the section on statistical analysis in the study protocol. He
contributed with GP, CS, and NM to the drafting and editing of thismanuscript and the interpretation of data for the work. All authors read
and approved the final manuscript.Funding
This study received a grant from the APICIL foundation in March 2014.
Author details
1CHU de Clermont-Ferrand, Inserm CIC 1405, Centre de Pharmacologie
Clinique, F-63003 Clermont-Ferrand, France. 2CHU de Clermont-Ferrand,
Délégation Recherche Clinique & Innovation - Villa annexe IFSI, 58 Rue
Montalembert, F-63003 Clermont-Ferrand, France. 3Clermont Université,
Université d’Auvergne, Pharmacologie Fondamentale et Clinique de la
Douleur, Laboratoire de Pharmacologie, Facultés de Médecine/Pharmacie,
F-63000 Clermont-Ferrand, France. 4Inserm, U1107 Neuro-Dol, F-63001
Clermont-Ferrand, France.
Received: 4 November 2014 Accepted: 17 March 2015References
1. Bannwarth B, Blotman F, Roué-Le Lay K, Caubère J-P, André E, Taïeb C.
Fibromyalgia syndrome in the general population of France: a prevalence
study. Joint Bone Spine. 2009;76:184–7.
2. Mease P. Fibromyalgia syndrome: review of clinical presentation,
pathogenesis, outcome measures, and treatment. J Rheumatol Suppl.
2005;75:6–21.
3. Branco JC, Cherin P, Montagne A, Bouroubi A. Multinational coordinator
study group. Longterm therapeutic response to milnacipran treatment for
fibromyalgia: a European 1-year extension study following a 3-month study.
J Rheumatol. 2011;38:1403–12.
4. Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Katz RS, Mease P, et al.
The American College of Rheumatology preliminary diagnostic criteria for
fibromyalgia and measurement of symptom severity. Arthritis Care Res.
2010;62:600–10.
5. Kosek E, Hansson P. Modulatory influence on somatosensory perception
from vibration and heterotopic noxious conditioning stimulation (HNCS) in
fibromyalgia patients and healthy subjects. Pain. 1997;70:41–51.
6. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in
fibromyalgia. Clin J Pain. 1997;13:189–96.
7. Sigurdsson A, Maixner W. Effects of experimental and clinical noxious
counterirritants on pain perception. Pain. 1994;57:265–75.
8. Edwards RR, Ness TJ, Weigent DA, Fillingim RB. Individual differences in
diffuse noxious inhibitory controls (DNIC): association with clinical variables.
Pain. 2003;106:427–37.
9. Staud R, Robinson ME, Vierck Jr CJ, Price DD. Diffuse noxious inhibitory
controls (DNIC) attenuate temporal summation of second pain in normal
males but not in normal females or fibromyalgia patients. Pain.
2003;101:167–74.
10. Van Wijk G, Veldhuijzen DS. Perspective on diffuse noxious inhibitory
controls as a model of endogenous pain modulation in clinical pain
syndromes. J Pain. 2010;11:408–19.
11. Pickering G, Pereira B, Dufour E, Soule S, Dubray C. Impaired modulation of
pain in patients with postherpetic neuralgia. Pain Res Manag. 2014;19:e19–23.
12. Yarnitsky D, Arendt-Nielsen L, Bouhassira D, Edwards RR, Fillingim RB, Granot
M, et al. Recommendations on terminology and practice of psychophysical
DNIC testing. Eur J Pain. 2010;14:339.
13. Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y.
Conditioned pain modulation predicts duloxetine efficacy in painful diabetic
neuropathy. Pain. 2012;153:1193–8.
14. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, et al.
EULAR evidence-based recommendations for the management of
fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536–41.
15. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al.
Efficacy and safety of duloxetine for treatment of fibromyalgia in patients
with or without major depressive disorder: results from a 6-month,
randomized, double-blind, placebo-controlled, fixed-dose trial. Pain.
2008;136:432–44.
16. Ormseth MJ, Eyler AE, Hammonds CL, Boomershine CS. Milnacipran for the
management of fibromyalgia syndrome. J Pain Res. 2010;3:15–24.
Macian et al. Trials  (2015) 16:134 Page 6 of 617. Palmer RH, Periclou A, Banerjee P. Milnacipran: a selective serotonin and
norepinephrine dual reuptake inhibitor for the management of
fibromyalgia. Ther Adv Musculoskelet Dis. 2010;2:201–20.
18. Arnold LM, Palmer RH, Ma Y. A 3-year, open-label, flexible-dosing study of
milnacipran for the treatment of fibromyalgia. Clin J Pain. 2013;29:1021–8.
19. Pickering G, Pereira B, Clère F, Sorel M, de Montgazon G, Navez M, et al.
Cognitive function in older patients with postherpetic neuralgia. Pain Pract
Off J World Inst Pain. 2014;14:E1–7.
20. Efird J. Blocked randomization with randomly selected block sizes. Int J
Environ Res Public Health. 2011;8(1):15–20.
21. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in
fibromyalgia is related to a deficit of endogenous pain inhibition. Pain.
2005;114(1–2):295–302.
22. Granovsky Y, Matre D, Sokolik A, Lorenz J, Casey KL. Thermoreceptive
innervation of human glabrous and hairy skin: a contact heat evoked
potential analysis. Pain. 2005;115:238–47.
23. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with
baseline and follow up measurements. BMJ. 2001;323(7321):1123–4.
24. Denk F, McMahon SB, Tracey I. Pain vulnerability: a neurobiological
perspective. Nat Neurosci. 2014;17:192–200.
25. Gendreau J, Palmer R, Thacker K. (170) Milnacipran is safe and well tolerated
in the treatment of fibromyalgia syndrome. J Pain. 2008;9(4, suppl, 2):18–8.
26. Yarnitsky D, Crispel Y, Eisenberg E, Granovsky Y, Ben-Nun A, Sprecher E,
et al. Prediction of chronic post-operative pain: pre-operative DNIC testing
identifies patients at risk. Pain. 2008;138:22–8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
